NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









LevitasBio

LevitasBio

Private
Hayward, CaliforniaHealthcare & Life Scienceshttps://levitasbio.com/

Last Round

Series C

Nov 7, 2022

Total Funding Raised

$61M

Company Overview

LevitasBio is a life sciences company that provides a label-free single-cell imaging and profiling platform for purifying cells and nuclei without markers or modifications.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Biotech Equipment, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Hardware Sales, Usage-Based SaaS, Services & Consulting

AI Layer

Non-AI

Keywords

cell isolationcell enrichmentlabel-free cell sortingfluorescence-activated cell sortingFACSsingle-cell analysisbiotech equipmentlevitation technologycell therapy developmenttissue dissociationbenchtop lab equipmentrazor and blades modelsample preparationmagnetic bead separationlab automation

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

LevitasBio Comparables

Compare LevitasBio with similar companies based on industry and business-model similarity.

LevitasBio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Deepcell
84%
NanoCellect Biomedical
84%
Cell Microsystems
82%

LevitasBio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CNov 7, 2022
Series BJan 6, 2021
Series AAug 3, 2017

Key People

Founding team and executive leadership

Martin Pieprzyk

Chief Executive Officer

Executive Team

LevitasBio Investors

Notable investors and investment history

LevitasBio investors
InvestorRounds
Wuhan Thalys Medical TechnologySeries B
Pavilion CapitalSeries C
Novalis LifeSciencesSeries C
EosSeries C
Decheng CapitalSeries C, Series B, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 7, 2022

    $35M round led by Novalis LifeSciences.

LevitasBio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

LevitasBio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about LevitasBio's valuation, stock price, and market status.

Firmographic Details

HeadquartersHayward, California
Employee Range28
Year Founded2017
Last FundingNov 7, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.